問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Digestive System Department

Division of General Internal Medicine

更新時間：2023-09-19

高嘉宏Kao, Jia-Horng
  • Principal Investigator
  • Clinical Trial Experience (year) 24 years 3 個月

Recruiting Trial

30Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

高嘉宏

List

106Cases

2015-09-16 - 2017-06-30

Phase III

An Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered with Ribavirin (RBV) in Treatment-Naïve and Treatment-Experienced Asian Adults with Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis

  • Condition/Disease

    Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis

  • Test Drug

    ABT-450/Ritonavir/ABT-267, ABT-333, Ribavirin

Participate Sites
6Sites

Terminated5Sites

朱啟仁
Taipei Veterans General Hospital

Digestive System Department

彭成元
China Medical University Hospital-Taipei

未分科

2009-10-31 - 2012-10-20

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2023-01-05 - 2026-12-31

Phase III

Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment With Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B Virus (B-Well 2)

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    GSK3228836/Bepirovirsen

Participate Sites
4Sites

Terminated4Sites

2007-08-01 - 2010-10-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2009-09-07 - 2012-01-22

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2015-09-01 - 2016-08-31

Others

STUDY TO EVALUATE EFFICACY, SAFETY AND PHARMACOKINETICS OF ASC16 (RAVIDASVIR) IN COMBINATION WITH RITONAVIR-BOOSTED ASC08 (DANOPREVIR) AND RIBAVIRIN IN TREATMENT-NAIVE NON-CIRRHOTIC TAIWANESE PATIENTS WHO HAVE CHRONIC HEPATITIS C GENOTYPE 1.

  • Condition/Disease

    Chronic Hepatitis C Genotype 1

  • Test Drug

    ASC16 & ASC08

Participate Sites
5Sites

Terminated5Sites

2007-03-01 - 2008-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2013-12-01 - 2016-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2017-02-01 - 2019-06-30

Others

A Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dose and Multiple Doses of GSK3389404 in Chronic Hepatitis B Subjects

  • Condition/Disease

    The plan includes adult male and female CHB subjects aged 18 to 70 (inclusive) who are not currently receiving CHB treatment. Part 1 (Groups A, B, C, and D) will include HBeAg-positive subjects, while Part 1 (Group C1) will include HBeAg-negative subjects. After completing part 1 of the administration (after reviewing the safety, tolerability, PK and PD differences between HBeAg status), the specific CHB group included in part 2 will be determined

  • Test Drug

    GSK3389404

Participate Sites
9Sites

Recruiting8Sites

2017-11-01 - 2021-12-31

Others

A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment(OAV) in Virologically Suppressed Chronic Hepatitis B Subjects with Renal and/or Hepatic Impairment

  • Condition/Disease

    Chronic viral hepatitis B

  • Test Drug

    Vemlidy Film-coated tablet

Participate Sites
10Sites

Terminated9Sites

莊萬龍
Kaohsiung Municipal Gangshan Hospital

未分科

林俊彥
Linkou Chang Gung Medical Foundation

1 4 5 6 7 8 11
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB